A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. - Garcia-Manero G; Podoltsev NA; Othus M; Pagel JM; Radich JP; Fang M; Rizzieri DA; Marcucci G; Strickland SA; Litzow MR; Savoie ML; Medeiros BC; et al. (Leukemia, 2024)